Monocyte-to-High Density Lipoprotein Cholesterol Ratio Correlates with the Presence of Cardiovascular Risk Factors in Patients Who Received Upfront Dexrazoxane During Anthracycline Treatment: A Single-Center Observation

Abstract

Objectives: In this study, we aimed to retrospectively analyze the baseline characteristics, blood parameters and cardiovascular risk factors of the patients who received dexrazoxane to prevent anthracycline-induced cardiotoxicity.Methods: The data of patients who applied to our hospital’s medical oncology clinic between March 2019 and August2019, were treated with anthracycline due to various malignancies and received primary prophylaxis with dexrazoxanewere retrospectively analyzed.Results: A total of 75 patients included in the study. It was observed that 81.3% (n=61) of the cases had at least onerisk factor for developing cardiac side effects. The risk factors of the cases ranged from 0 to 4, with a mean of 1.45. As ofAugust 2019, none of the patients had any symptoms related with cardiac dysfunction A positive correlation betweenglucose (r=0.234; p=0.044), creatinine (r=0.380; p=0.001), monocyte (r=0.232; p=0.046), triglyceride (r=0.252; p=0.033)measurements of the subjects and the number of risk factors was found. A significant positive correlation analyses wasfound between the monocyte-to-HDL ratio (MHR) (r=0.233; p=0.048) of the subjects and the number of risk factors.Conclusion: We suggest that dexrazoxane is an important cardioprotective agent that have a huge potential on preventing the long-term cardiotoxicity, and blood parameters especially those which represents the state of inflammation in the body such as MHR should be utilized when assessing the cardiovascular risks of each patient.